Prospective observational study on the impact of vaccination against COVID-19 in patients with hematopoietic tumors

Prospective observational study on the impact of vaccination against COVID-19 in patients with hematopoietic tumors - Prospective observational study on the impact of vaccination against COVID-19 in patients with hematopoietic tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049407

Enrollment

200

Registered

2022-11-02

Start date

2021-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematopoietic tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age 16 years or older at the time of consent 2) Patients with hematopoietic tumors attending or hospitalized at the National Cancer Center Hospital 3) Adults whose written consent for this study has been obtained by the patient or a surrogate. 3) Adults for whom written consent for this study has been obtained by the individual or a surrogate, or minors for whom written consent for this study has been obtained by the individual and a surrogate. 4) Patients with hematopoietic tumors who are receiving or have received the following chemotherapy regimens (a small number of patients with hematopoietic tumors on no treatment or receiving/post receiving other chemotherapy regimens may be included) B-cell antibody (rituximab/obinutuzumab) and or chemotherapy CAR-T therapy Dual-specificity antibody agents BTK inhibitors 5) Scheduled or post (within 3 months) vaccination with novel coronavirus vaccine

Exclusion criteria

Exclusion criteria: 1) Subjects whom the principal investigator or physician in charge determines are not appropriate for this study 2) Patients after allogeneic hematopoietic stem cell transplantation

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 antibody positivity after vaccination	—

Countries

Japan

Contacts

Public ContactYuki Katsuya

National Cancer Center Hospital Department of experimental development

ykatsuya@ncc.go.jp0335422511

Outcome results